PGNX News and Press, Progenics Pharmaceuticals Inc. From 10/23/19

Progenics Has Again Resorted to False Information and Misleading Innuendo in Seemingly Desperate Attempt to Avoid Accountability and Deprive Stockholders of Chance to Realize Company’s Full Value Velan Purchased Progenics Stock Because of Conviction in Company’s Opportuni...

Flags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan’s Questionable Securities Trading, Governance and Ethical Practices Asks Velan’s Nominees if They Want to Be Associated with These Questionab...

On October 2nd, Lantheus Holdings ( LNTH ) Progenics Pharmaceuticals ( PGNX ), announced an agreement for Lantheus to acquire Progenics in an all-stock transaction. According to the press release, "the transaction has been unanimously approved by the Boards of Directors of both companies." U...

In Velan’s View, Proposed Lantheus Transaction Illustrates Worst Attributes of Progenics Board in Action Believes Current Progenics Board Cannot be Trusted to Represent Best Interests of Stockholders Highlights Company’s Inaccurate and Misleading Statements Related...

Plan Highlights Nominees’ Skill Sets and Expertise that Velan Believes Would Lead to Improvements in Company’s Culture, Operational Execution, Financial Standing, Governance, Leadership and Strategy In Velan’s View, CEO Mark Baker and Current Board Must Be Held Acc...

Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders Urges Shareholders to Sign and Return Progenics’ WHITE...

Believes a Reconstituted Board is Immediately Needed to Reverse Strategic, Operational and Oversight Failures at the Company Urges Stockholders to Continue to Make their Voices Heard Following 2019 Annual Meeting Believes Recently-Announced Lantheus Transaction Massively Underval...

Merger activity increased last week with five new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Dova Pharmaceuticals (DOVA) by Swedish Orphan Biovitrum AB (BIOVF) for $915 million. Under the terms of the agreement, Dova stockholders will ...

Lantheus Holdings' ( LNTH -20.9% ) all-stock deal to buy Progenics Pharmaceuticals ( PGNX +9.8% ) substantially undervalues the target company, says one of Progenics' biggest shareholders. More news on: Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news,...

Believes Company’s Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard Views Progenics’ Potential Value Under Appropriate Leadership to be Substantially Higher Tha...